Guillain-barré syndrome and chronic inflammatory demyelinating polyneuropathy

Seminars in Neurology

Volumn 18, Issue 1, 1998, Pages 49-61

  Barohn, Richard J ^a   Saperstein, David S ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Chronic inflammatory demyelinating polyneuropathy; Guillain barr syndrome; Neuropathy

Indexed keywords

DEMYELINATING DISEASE; HUMAN; MEDICAL EDUCATION; POLYRADICULONEUROPATHY; REVIEW;

DEMYELINATING DISEASES; EDUCATION, MEDICAL, CONTINUING; HUMANS; POLYRADICULONEUROPATHY;

EID: 0031630443     PISSN: 02718235     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2008-1040861     Document Type: Article

References (112)

1. Ropper AH, Wijdicks EFM, Truax BT. Guillain-Barré Syndrome. Philadelphia: FA Davis; 1991
2. Ropper AH. The Guillain-Barre syndrome. N Engl J Med 1992; 326:1130-1136
3. Parry GJ. Guillain-Barré Syndrome. New York: Thieme Medical Publishers, Inc; 1993
4. Asbury AK, Arnason BG, Adams RD. The inflammatory lesion in idiopathic polyneuritis. Its role in pathogenesis. Medicine 1969;48:173-215
5. Hartung HP, Pollard JD, Harvey GK, Toyka KV. Immunopathogenesis and treatment of the Guillain-Barré syndromePart 1 and Part 2. Muscle Nerve 1995;18:137-153, 154-164
6. Alter M. The epidemiology of Guillain-Barré syndrome. Ann Neurol 1990;27(suppl):S7-12
7. Rees JH, Soudain SE, Gregson NA, Hughes RA. Campylobacler jejiuii infection and Guillain-Barré syndrome. N Engl J Med 1995;333:1415-1417
8. Bolton CF. The changing concepts of Guillain-Barré syndrome. N Engl J Med 1995;333:1415-1417
9. Griffin JW, Ho TW. The Guillain-Barré syndrome at 75: The Campylobacter connection. Ann Neurol 1993;34:125-127
10. Blaser MJ. Campylobacter species. In Mandell GL, Douglas RG, Bennett JE, eds. Principles and Practice of Infectious Diseases. 4th ed. New York: Churchill Livingstone; 1995:1649-1658
11. Yuki N, Takahashi M, Tagawa Y, et al. Association of Campylobacterjejimi serotype with antiganglioside antibody in Guillain-Barré syndrome and Fisher's syndrome. Ann Neurol 1997;42:28-33
12. Arnason BG, Asbury AK. Idiopathic polyneuritis after surgery. Arch Neurol 1968;18:500-507
13. Löffel NB, Rossi LN, Mumenthaler M, Lutschg J, Ludin HP. The Landry-Guillain-Barré syndrome. Complications, prognosis, and natural history in 123 cases. J Neurol Sci 1977;33:71-79
14. Gibbles E, Giebisch U. Natural course of acute and chronic monophasic inflammatory demyelinating polyneuropathies (IDP).Acta Neurol Scand 199I;85:282-29I
15. Asbury AK, Cornblath DR. Assessment of current diagnostic criteria for Guillain-Barré syndrome. Ann Neurol 1990;27 (suppl):S21-24
16. Fisher CM. An unusual variant of acute idiopathic poly-neuritis (syndrome of ophthalmoplegia, ataxia, and areflexia). N Engl J Med 1956:255:57-65
17. Ropper AH. Unusual clinical variants and signs in Guillain-Barré syndrome. Arch Neurol 1986;43:1150-1152
18. Ropper AH. Further regional variants of acute immune polyneuropathy. Arch Neurol 1994:51:671-675
19. Simmons Z, Tivakaran S. Acquired demyelinating polyneuropathy presenting as a pure clinical sensory syndrome. Muscle Nerve 1996;19:1174-1176
20. Feasby TE, Gilbert JJ, Brown \VF, et al. An acute axonal form of Guillain-Barré polyneuropathy. Brain 1986;109:1115-1126
21. Ramos-Alvarez M, Bessudo L, Sabin A. Paralytic syndromes associated with noninflammatory cytoplasmic or nuclear neuronopathy: Acute paralytic disease in Mexican children, neuropathologically distinguishable from Landry-GuillainBarré syndrome. JAMA 1969;207:1481-1492
22. Valencio L, Najera E, Perez Gallardo F, Gonzalez A, et al. Outbreak of paralytic illness of unknown etiology in Albacete, Spain. Am J Epidemiol 1971;94:450-456
23. Jackson CE, Barohn RJ, Mendell JR. Acute paralytic syndrome in three American men: Comparison with Chinese cases. Arch Neurol 1993;50:732-735
24. McKhann GM, Cornblath DR, Griffin JW, et al. Acute motor axonal neuropathy: A frequent cause of acute flaccid paralysis in China. Ann Neurol 1993;33:333-342
25. Griffin JW, Li CY, Ho TW, et al. Pathology of the motor-sensory axonal Guillain-Barré syndrome. Ann Neurol 1996:39:17-28
26. Cornblath DR, McArthur JC, Kennedy PG, Witte AS, Griffin JW. Inflammatory demyelinating peripheral neuropathies associated with human T-cell lymphotrophic virus type III infection. Ann Neurol 1987:21:32-40
27. Albers JW, Donofrio PD, McGonable TK. Sequential electrodiagnostic abnormalities in acute inflammatory demyelinating polyradiculoneuropathy. Muscle Nerve 1985:8:528-539
28. Cornblath D. Eleclrophysiology in Guillain-Barré syndrome. AnnNeurol 1990;27(suppl):S 17-20
29. Comblath DR, Mellits ED, Griffin J\V, et al. Motor conduction studies in Guillain-Barré syndrome: Description and prognostic value. Ann Neurol 1988:23:354-359
30. Anders BJ, Lauer BA, Paisley JW, Relier LB. Double-blind placebo controlled trial of erythromycin for treatment of Campylobacter enteritis. Lancet 1982;1:131-134
31. Vriesendorp FJ, Mishu B, Blaser MJ, Koski CL. Serum antibodies to GM1, GDlb, peripheral nenfe myelin, and Campylobacter jejuni in patients with Guillain-Barré syndrome and controls: Correlation and prognosis. Ann Neurol 1993:34:130-135
32. Ilyas AA, Willison HG, Quarles RH, et al. Serum antibodies to gangliosides in Guillain-Barré syndrome. Ann Neurol 1988; 23:440-447
33. van der Mèche FGA, van Doom PA. Guillain-Barre syndrome and chronic inflammatory demyelinating polyneuropathy: Immune mechanisms and update on current therapies. Ann Neurol 1995;37(S1):S14-31
34. 1 IgG antibodies and Campylobacter bacteria in Guillain-Barré syndrome: Evidence of molecular mimicry. Ann Neurol 1995;38:170-175
35. Rees JH, Gregson NA, Hughes RÄ. Anti-ganglioside GM1 antibodies in Guillain-Barré syndrome and their relationship to Campylobacter jejuni infection. Ann Neurol 1995;38:809-816
36. Willison HJ, Veitch J, Paterson G, Kennedy PG. Miller Fisher syndrome is associated with serum antibodies to GQlb ganglioside. J Neurol Neurosurg Psychiatry 1993;56:204-206
37. Yuki N, Sato S, Tsuji S, Ohsawa T, Miyatake T. Frequent presence of anti-GQlb antibody in Fisher's syndrome. Neurology 1993:43:414-417
38. Morgan GW, Barohn RJ, Bazan C, King RB, Klucznik RP. Nerve root enhancement with MRI in inflammatory demyelinating polyradiculoneuropathy. Neurology 1993;43:618-620
39. Perry JR, Fung A, Pöon P, Bayer N. Magnetic resonance imaging of nerve root inflammation in the Guillain-Barré syndrome. Neuroradiology 1994;36:139-140.
40. Crino PB, Zimmerman R, Laskowitz D, et al. Magnetic reso. nance imaging of the cauda equina in Guillain-Barré syndrome. Neurology 1994;44:1334-1336
41. Gorson KC, Ropper AH, Muriello A, Blair R. Prospective evaluation of MRI lumbosacral nerve root enhancement in acute Guillain-Barré syndrome. Neurology 1996;47:813-817
42. Griffin JW, Li CY, Ho TW, et al. Guillain-Barré syndrome in northern China: The spectrum of neuropathologic changes in clinically defined cases. Brain 1995:118:577-595
43. McKhann GM, Griffin JW, Cornblath DR, et al. Plasmapheresis and Guillain-Barré syndrome: Analysis of prognostic factors and the effect of plasmapheresis. Ann Neurol 1988;23:347-353
44. Visser LH, van der Mèche FGA, Meulstee J, et al. Cytomegalovirus infection and Guillain-Barré syndrome: The clinical, electrophysiologic, and prognostic features. Neurology 1996;47: 668-673
45. Ho TW, Hsieh ST, Nachamkin I, et al. Motor nerve terminal degeneration provides a potential mechanism for rapid recovery in acute motor axonal neuropathy after Campylobacter infection. Neurology 1997:48:717-724
46. Ho TW, Li CY, Cornblath DR, et al. Patterns of recovery in the Guillain-Barré syndromes. Neurology 1997;48:695-700
47. French Cooperative Group on Plasma Exchange in GuillainBarré Syndrome: Role of replacement fluids. Ann Neurol 1987:22:753-761.
48. Wijdicks EFM, Ropper AH. Acute relapsing Guillain-Barré syndrome after long asymptomatic intervals. Arch Neurol 1990; 47:82-84
49. Guillain-Barré Syndrome Study Group. Plasmapheresis and acute Guillain-Barré syndrome. Neurology 1985;35:1096-1104
50. The French Cooperative Group on Plasma Exchange in Guillain-Barré Syndrome. Appropriate number of plasma exchanges in Guillain-Barré syndrome. Ann Neurol 1997;41: 298-306
51. van der Mèche FGA, Schmilz P1M, and the Dutch Guillain-Barre Study Group. A randomized trial comparing intravenous immune
52. globulin and plasma exchange in Guillain-Barre syndrome. N Engl J Med 1992;326:1123-1129
53. Plasma Exchange/Sandoglobulin Guillain Barré Syndrome Trial Group. Randomized trial of plasma exchange, intravenous immunoglobulin, and combined treatments in Guillain Barré syndrome. Lancet 1997;349:225-230
54. Bjoro K, Froland SS, Yun Z, Samdal HH, Haaland T. Hepatitis C infection in patients with primary hypogammaglobulinemia after treatment with contaminated immune-globulin. N Engl J Medl994;331:1607-1611
55. Schiff RI. Transmission of viral infections through intravenous immune globulin [editorial]. N Engl J Med 1994:331:1649-1650
56. Irani DN, Cornblath DR, Chaudhry V, Borel C, Hanley DF. Relapse in Guillain-Barré syndrome after treatment with human immune globulin. Neurology 1993;43:872-875
57. Castro LHM, Ropper AH. Human immune globulin infusion in Guillain-Barré syndrome: Worsening during and after treatment. Neurology 1993;43:1034-I036
58. Bleck TP. IVIG for GBS: Potential problems in the alphabet soup. Neurology 1993;43:857-858
59. Ropper AH, Albers J\V, Addison R. Limited relapse in GuillainBarré syndrome after plasma exchange. Arch Neurol 1988;45: 314-315
60. Bril V, Use WK, Pearce R, et al. Pilot trial of immunoglobulin versus plasma exchange in patients with Guillain-Barré syndrome. Neurology 1996;46:100-103
61. Hughes RAC, Newsom-Davis J, Perkin CD, Pierce JM. Controlled trial of prednisolone in acute polyneuropathy. Lancet 1978;2:750-753
62. Guillain-Barre Syndrome Steroid Trial Group. Double-blind trial of intravenous methylprednisolone in Guillain-Barré syndrome. Lancet 1993;341:586-590
63. The Dutch Guillain-Barré Study Group. Treatment of GuillainBarré syndrome with high-dose immune globulins combined with methylprednisolone: A pilot study. Ann Neurol 1994;35: 749-752
64. Austin JH. Recurrent polyneuropathies and their corticosteroid treatment. Brain 1958;81:157-194
65. Dyck PJ, Lais AC, Ohta M, et al. Chronic inflammatory demyelinating polyradiculoneuropathy. Mayo Clin Proc 1975;50: 621-637
66. 64a. Dyck PJ, Oviatt KF, Lambert EH. Intensive evaluation of referred unclassified neuropathies yields improved diagnosis. Ann Neurol 1981:10:222-226
67. Barohn RJ, Kissel JT, Warmolts JR, Mendell JR. Chronic inflammatory demyelinating polyradiculoneuropathy: Clinical characteristics, course, and recommendations for diagnostic criteria. Arch Neurol 1989;46:878-884
68. Ad Hoc Subcommittee of the American Academy of Neurology AIDS Task Force. Research criteria for diagnosis of chronic inflammatory demyelinating polyneuropathy (CIDP). Neurology 1991:41:617-618
69. Mendell JR. Chronic inflammatory demyelinating polyradiculoneuropathy. Annu Rev Med 1993;44:211-219
70. Prineas JW, McLeod JG. Chronic relapsing polyneuritis. J Neurol Sci 1976;27:427-158
71. Steck AJ. Inflammatory neuropathy: Pathogenesis and clinical features. CurrOpin Neurol Neurosurg 1992;5:633-637
72. Bromberg MB. Comparison of electrodiagnostic criteria for primary demyelination in chronic polyneuropathy. Muscle Nerve 1991:14:968-976
73. Cornblath DR, Griffin DE, Welch D, Griffin JW, McArthur JC. Quantitative analysis of endoneurial T-cells in human sural nerve biopsies. J Neuroimmunol 1990:26:113-118
74. Matsummuro K, Izumo S, Umehara F, Osame M. Chronic inflammatory demyelinating polyneuropathy: Histological and immunopathological studies in biopsied sural nerves. J Neurol Sci 1994:127:170-178
75. Kissel JT, Mendell JR. Neuropathies associated with monoclonal gammopathies. Neuromusc Disord 1995:6:3-18
76. Nobile-Orazio E, Latov N, Hays AP, et al. Neuropathy and antiMAG antibodies without detectable serum M-protein. Neuroln ogy 1984:34:218-221
77. Romanick-Schmiedl S, Kiprov D, Chalmers AC, Miller RG. Extraneural manifestations of chronic inflammatory demyelinating polyradiculoneuropathy. Am J Med 1990;89:531-534
78. Stewart JD, McKelvey R, Durcan L, Carpenter S, Karpati G. Chronic inflammatory demyelinating polyneuropathy (CIDP) in diabetics. J Neurol Sci 1996;142:59-64
79. Amato AA, Barohn RJ, Sahenk Z, Tutschka PJ, Mendell JR. Polyneuropathy complicating bone marrow and solid organ transplantation. Neurology 1993;43:1513-1518
80. Mendell JR, Kolkin S, Kissel JT, et al. Evidence for central nervous system demyelination in chronic inflammatory demyelinating polyradiculoneuropathy. Neurology 1987:37:1291-1294
81. Thomas PK, Walker RWH, Rudge P, et al. Chronic demyelinating peripheral neuropathy associated with multifocal central nervous system demyelination. Brain 1987; 110:53-76
82. Oh SJ, Joy JL, Sunwoo in, Kuruoght R. A case of chronic sensory demyelinating neuropathy responding to immunothérapies. Muscle Nerve 1992:15:255-256
83. Chroni E, Hall SM, Hughes RAC. Chronic relapsing axonal neuropathy: A first case report. Ann Neurol 1995;37:112-115
84. Uncini A, Sabatelli M, Mignogna T, et al. Chronic progressive steroid responsive axonal polyneuropathy: A CIDP variant or a primary axonal disorder? Muscle Nerve 1996;19:365-371
85. Hughes R, Sanders E, Hall S, et al. Subacute idiopathic demyelinating polyradiculoneuropathy. Arch Neurol 1992;49:612-616
86. Dyck PJ, O'Brien PC, Oviatt KF, et al. Prednisone improves chronic inflammatory demyelinating polyradiculoneuropathy more than no treatment. Ann Neurol 1982;11:136-141
87. Dyck PJ, Daube J, O'Brien P, et al. Plasma exchange in chronic inflammatory demyelinating polyradiculoneuropathy. N Engl J Med 1986;3I4:461-465
88. Hahn AF, Bolton CF, Pillay N, et al. Plasma-exchange therapy in chronic inflammatory demyelinating polyneuropathy: A double-blind, sham-controlled, cross-over study. Brain 1996;119: 1055-1066
89. Hahn AF.'Bolton CF, Zochodne D, Feasby TE. Intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyneuropathy: A double-blind, placebo-controlled, crossover study. Brain 1996; II9:1067-1077
90. van Doom PA, Brand A, Strengers PFW, Meulstee J, Vermeulen M. High-dose intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyneuropathy: A double-blind, placebo-controlled crossover study. Neurology 1990;40:209-212
91. van Doom PA, Vermeulen M, Brand A, Mulder PGH, Busch HFM. Intravenous immunoglobulin treatment in patients with chronic inflammatory demyelinating polyneuropathy. Clinical and laboratory characteristics associated with improvement. Arch Neurol 1991;48:217-220
92. Vermeulen M, van Doom PA, Brand A, et al. Intravenous immunoglobulin treatment in patients with chronic inflammatory demyelinating polyneuropathy: A double-blind, placebo-controlled study. J Neurol Neurosurg Psychiatry 1993:56:36-39
93. Dyck PJ, Litchy WJ, Kratz KM, et al. A plasma exchange versus immune globulin infusion trial in chronic inflammatory demyelinating polyradiculoneuropathy. Ann Neurol 1994;36:838-845
94. Dyck PJ, O'Brien P, Swanson C, Low P, Daube J. Combined azathioprine and prednisone in chronic inflammatory demyelinating polyneuropathy. Neurology 1985;35:1173-1176
95. Kolkin S, Nahman NS, Mendell JR. Chronic nephrotoxicity complicating cyclosporine treatment of chronic inflammatory demyelinating polyradiculoneuropathy. Neurology 1987;37:147-149
96. Mahattanakul WO, Crawford T, Griffin J\V, Goldstein JM, Cornblath DR. Treatment of chronic inflammatory demyelinating polyneuropathy with cyclosporin-A. J Neurol Neurosurg Psychiatry 1996:60:186-187
97. Sabatelli M, Mignona T, Lippi G, et al. Interferon-alpha may benefit steroid unresponsive chronic inflammatory demyelinating polyneuropathy. J Neurol Neurosurg Psychiatry 1995; 58:638-639
98. Gorson KC, Allam G, Simovic D, Ropper AH. Improvement following interferon-alpha 2A in chronic inflammatory demyelinating polyneuropathy. Neurology 1997;48:777-780
99. Choudhary PP, Thopson N, Hughes RAC. Improvement following interferon-beta in chronic inflammatory demyelinating polyneuropathy. J Neurol 1995;242:252-253
100. Gorson KC, Allam G, Ropper AH. Chronic inflammatory demyelinating polyneuropathy: Clinical features and response to treatment in 67 consecutive patients with and without a monoclonal gammopathy. Neurology 1997 ;48:321-328
101. Dyck PJ, Low PA, Windebank AJ, et al. Plasma exchange in polyneuropathy associated with monoclonal gammopathy of undetermined significance. N Engl J Med 1991;325:1482-1486
102. Yeung KB, Thomas PK, King RHM, et al. The clinical spectrum of peripheral neuropathies associated with benign monoclonal IgM, IgG and IgA paraproteinaemia. J Neurol 1991:238:383-391
103. Notermans NC, Wokke JHJ, van den Berg LH, et al. Chronic idiopathic axonal polyneuropathy comparison of patients with and without monoclonal gammopathy. Brain 1996;119:421-427
104. Dalakas MC, Quarles RH, Fairer RG, et al. A controlled study of intravenous immunoglobulin in demyelinating neuropathy with IgM gammopathy. Ann Neurol 1996;40:792-795
105. Simmons Z, Albers JW, Bromberg MB, Feldman EL. Presentation and initial clinical course in patients with chronic inflammatory demyelinating polyradiculoneuropathy: Comparison of patients without and with monoclonal gammopathy. Neurology 1993;43:2202-2209
106. Simmons Z, Albers JW, Bromberg MB, Feldman EL. Long-term followup of patients with chronic inflammatory demyelinating polyradiculoneuopathy, without and with monoclonal gammopathy. Brain 1995;118:359-368
107. Latov N, Sherman WH, Hays AP. Peripheral neuropathy and antiMAG antibodies. CRC Crit Rev Neurobiol 1988;3:301-332.
108. Nobile-Orazio E, Baldini L, Barbieri S, et al. Treatment of patients with neuropathy and anti-MAG M-proteins. Ann Neurol 1988;24:93-97
109. Blume G, Pestronk A, Goodnough LT. Anti-MAG antibody-associated polyneuropathies: Improvement following immunotherapy with monthly plasma exchange and IV cyclophosphamide. Neurology 1995;45:1577-1580
110. Cook D, Dalakas M, Galdi A, et al. High-dose intravenous immunoglobulin in the treatment of demyelinating neuropathy associated with monoclonal gammopathy. Neurology 1990;40: 212-214
111. Leger JM, Younes-Chennoufi AB, Chassandro B, et al. Human immunoglobulin treatment of multifocal motor neuropathy and polyneuropathy associated with monoclonal gammopathy. J Neurol Neurosurg Psychiatry 1994;57(suppl):46-49
112. Mariette X, Chastang C, Clavelou P, et al. A randomised clinical trial comparing interferon-oc and intravenous immunoglobulin in polyneuropathy associated with monoclonal IgM. J Neurol Neurosurg Psychiatry 1997;63:28-34